Antibiotic treatments to clear first Pseudomonas aeruginosa infection in bronchiectasis
Compares 3 antibiotic regimens with placebo in adults with bronchiectasis and new Pseudomonas aeruginosa infection.
Key facts
- Who runs it
- Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
- Where
- Barcelona, Getafe, L'hospitalet De Llobregat, Lleida, Madrid, Málaga, Manresa, Martorell, and Oviedo, SpainSee the 13 sites
- Trial code
- Registry title
- PRIME Trial - Primary Respiratory Infection and Microbiological Eradication Trial
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 160 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 1 Mar 2029
- Type of study
- Interventional
- Record updated
- 9 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bronchiectasis not caused by cystic fibrosis who have a new (primary) infection with the germ P. aeruginosa (PA) in the lungs.
- Age
- Over 18 years (the record also lists 18 years as the minimum age).
- Sex
- All sexes can join.
- Disease stage
- Bronchiectasis not caused by cystic fibrosis (NCFB), diagnosed from symptoms and HRCT lung scan within the last five years. People must be stable: no flare-up in the past month, no need for intravenous medicines or hospital stay.
- Earlier treatment
- People cannot be on long-term antibiotic therapy. For a 'new isolation', there must be no long-term anti-PA treatment in the past year. For 'PA persistence', PA must remain four weeks after oral or intravenous antibiotics given for a flare-up.
- Biomarker or test result
- PA found in a sputum or bronchoscopy sample, either for the first time ever, still present after antibiotics, or again after at least three negative cultures in the past year (at least one month apart).
Main reasons for not taking part
- PA resistant to the study drugs, or infection with other bacteria
- Cannot take ciprofloxacin or colistin, or cannot tolerate nebulized inhaled treatment
- Cystic fibrosis, uncontrolled asthma, tuberculosis or a weakened immune system
- Kidney filtration rate (glomerular filtration rate) below 30 ml/min/1.73 m²
- Pregnant or breastfeeding women, or women who can have children and do not use highly effective contraception
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults aged >18 years
- Diagnosis of NCFB based on clinical symptoms and HRCT imaging within the last five years
- Primary PA infection, identified by isolation of PA from a respiratory sample, meeting one of the following criteria: -First isolation: The patient has never had a positive culture for PA from a respiratory sample* before. -PA persistence: The patient had a first isolation of PA from a respiratory sample during an exacerbation, followed by systemic antibiotic treatment (oral or intravenous), with PA persisting in a respiratory sample four weeks after the completion of treatment. -New isolation: The patient had a prior positive culture for PA from a respiratory sample, with at least three negative cultures for PA over the preceding year (spaced at least one month apart) without chronic antipseudomonal treatment during this period. * Respiratory sample: sputum or bronchoscopic sample obtained during routine clinical practice
- Clinically stable at the time of inclusion: no exacerbations in the past month and no need for intravenous medications or hospitalization
- Signed informed consent
Who cannot take part
- Patients with contraindications to the study medications (ciprofloxacin or colistin)
- Patients receiving chronic antibiotic therapy
- Infection with PA resistant to the treatments under investigation or infection with other bacteria
- Patients with a history of intolerance to inhaled treatment via nebulization
- Patients with cystic fibrosis, uncontrolled asthma, tuberculosis, or immunosuppression
- Patients with uncontrolled systemic diseases within the last 3 months
- Women of childbearing age not using a highly effective contraceptive method
- Patients participating in other clinical trials
- Refusal to participate
- Patients with a glomerular filtration rate < 30 ml/min/1.73 m²
- Pregnant or breastfeeding women
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
- Hospital de la Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital Universitario de GetafeGetafe, SpainNot yet recruiting
- Bellvitge University HospitalL'hospitalet De Llobregat, SpainNot yet recruiting
- Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De LleidaLleida, SpainNot yet recruiting
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario La PazMadrid, SpainNot yet recruiting
- Hospital Universitario Regional de MálagaMálaga, SpainNot yet recruiting
- Althaia Xarxa Assistencial Universitaria De Manresa Fundacio PrivadaManresa, SpainNot yet recruiting
- Fundacio Hospital Sant Joan De Deu De MartorellMartorell, SpainNot yet recruiting
- Hospital Universitario Central De AsturiasOviedo, SpainNot yet recruiting
About the trial
What the trial wants to find out
The primary objective of this study is to evaluate the efficacy of three different antibiotic regimens, compared to placebo, for the eradication of PA in adults with NCFB and primary PA infection. The primary outcome will focus on microbiological eradication, which will be assessed through negative cultures at 3 months after treatment initiation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Randomized, double-blind, parallel-group clinical trial, compared with placebo to evaluate the efficacy and safety of three antibiotic treatment regimens for the eradication of primary P. aeruginosa infection in patients with bronchiectasis
- Plain-language title
- Antibiotic treatments to clear first Pseudomonas aeruginosa infection in bronchiectasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 9 June 2026